Skip to main content

Table 1 Demographics of the patients received systemic, inhaler and systemic colistin therapy

From: Is inhaled colistin beneficial in ventilator associated pneumonia or nosocomial pneumonia caused by Acinetobacter baumannii?

  PE colistin
(n=80)
PE and inh.
colistin
p
n (%) n (%)
Age ± SD 62.80 ± 18.80 66.67 ± 15.49 0.290
Gender (M/F) 50/30 33/10 0.109
Cause of admission   0.386
 Respiratory failure 26 (32.5) 6 (14) 0.025
 Septic shock 3 (3.8) 4 (9.3) 0.205
 Trauma 7 (8.8) 4 (9.3) 0.010
 Post-op resuscitation 10 (12.5) 9 (20.9) 0.217
 Acute neurological disorder 29 (36.3) 18 (41.9) 0.541
 Cardiac arrest 5 (6.3) 2 (4.7) 0.715
Duration of ICU stay ± SD 57.68 ± 56.99 47.91 ± 47.02 0.514
Duration of colistin therapy ± SD 11.21 ± 6.714 11.23 ± 6.023 0.708
Infection
 HKP 25 (31.3) 15 (34.9) 0.681
 VIP 55 (68.7) 28 (65.1) 0.681
 Creatinine at baseline ± SD 0.82 ± 0.56 1.20 ± 0.89 0.009
 Creatinine at end-of-treatment ± SD 1.65 ± 1.08 1.86 ± 1.22 0.469
 Nephrotoxic drug use 43 (53.8) 23 (53.5) 0.978
Underlying disorders
 Cerebrovascular event 17 (21.3) 11 (25.6) 0.584
 COPD 6 (7.5) 3 (7) 0.915
 CAD 28 (35) 22 (51.2) 0.081
 Diabetes mellitus 19 (23.8) 10 (23.3) 0.950
 CRF 5 (6.3) 3 (7) 0.876
Concomitant antibiotics
 Carbapenem 62 (77.5) 36 (83.7) 0.413
 Cefoperazon
sulbactam
9 (11.3) 6 (14) 0.662
 Tigecycline 5 (6.3) 2 (4.7) 0.715
 Sulbactam 2 (2.5) 2 (4.7) 0.521
 Ceftazidime 1 (1.3) 0 (0) 0.461
  1. PE parenteral; Inh inhaled use